In the wake of the Pennsylvania Superior Court’s recognition of a new pharmaceutical liability cause of action, drugmaker Pfizer is asking the appeals court to reconsider or hold a new en banc argument on its ruling that plaintiffs can sue pharmaceutical companies for the allegedly negligent design of their products.
The panel of Judges Cheryl Lynn Allen, Correale F. Stevens and Susan Peikes Gantman ruled Aug. 6 that a negligent design defect claim regarding pharmaceutical drugs is distinct from a strict liability design defect claim and can be recognized in Pennsylvania. Gantman concurred in the result only.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]